Lineage Cell Therapeutics
LCTX
LCTX
96 hedge funds and large institutions have $63.2M invested in Lineage Cell Therapeutics in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 27 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
11% less capital invested
Capital invested by funds: $71.2M → $63.2M (-$8.04M)
22% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 27
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
Holders
96
Holding in Top 10
3
Calls
$20K
Puts
$12K
Top Buyers
| 1 | +$194K | |
| 2 | +$163K | |
| 3 | +$139K | |
| 4 |
State Street
Boston,
Massachusetts
|
+$114K |
| 5 |
Nuveen Asset Management
Chicago,
Illinois
|
+$71.1K |
Top Sellers
| 1 | -$318K | |
| 2 | -$135K | |
| 3 | -$85.1K | |
| 4 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
-$85K |
| 5 |
Barclays
London,
United Kingdom
|
-$79K |